Deal-hungry Perrigo elbows aside competitors for Omega Pharma

Deal-hungry Perrigo ($PRGO) is looking for more seats at the over-the-counter table, and the drugmaker may soon get its wish. The company is said to be close to sealing the deal for Belgian OTC maker Omega Pharma, inching past big-name competitors like Sanofi ($SNY), Actavis ($ACT) and Boehringer Ingelheim.

As Bloomberg reports, the drugmaker has entered exclusive talks to purchase Omega Pharma for €4 billion ($5 billion), people familiar with the matter told the news outlet. The deal would deliver Perrigo some much-sought-after OTC clout, as the Belgian drugmaker boasts about 2,000 brands, including painkiller Solpadeine. Not to mention the company's €1.2 billion ($1.6 billion) in sales last year thanks to standout performances in Europe and Russia--a 16% jump on the previous year's numbers.

Perrigo is no stranger to M&A; the company snatched up Elan ($ELN) last July for $8.6 billion, shifting its domicile to Ireland to reap the benefits of a lower tax rate and expanding its footprint abroad.

And Perrigo is not the only one looking for more OTC firepower. Novartis ($NVS) and GlaxoSmithKline ($GSK) have agreed to launch a consumer health JV that could catapult the team to the number one spot in the market. Bayer picked up Merck's consumer unit in May for $14.2 billion, outbidding the likes of Sanofi, Novartis and Reckitt Benckiser. The move is expected to create a business that generated $7.4 billion in combined 2013 sales, a "major milestone" on the company's path toward global leadership in nonprescription medicines, Bayer CEO Marjin Dekkers said at the time of the deal.

Meanwhile, some pharma M&A has stalled, thanks to new U.S. guidelines making it more difficult for companies to move abroad for tax-paying purposes. Earlier this month, Salix Pharmaceuticals ($SLXP) dropped its tax inversion deal for Cosmo Pharmaceuticals ($COPN), and AbbVie ($ABBV) called off its pending $55 billion deal for Dublin-based Shire ($SHPG).

- read the Bloomberg story

Special Report: Top 11 Fastest-Growing Generics Companies - Perrigo

Suggested Articles

Turns out Procter & Gamble didn’t want Pfizer’s consumer health unit after all. But it did want Merck KGaA’s.

Private equity firm, in exclusive talks with Sanofi, says it'll invest to pump up Zentiva into an "independent European generics leader."

With suitor Takeda circling Shire, the Dublin-based target has pulled off a deal of its own.